You are here

Xconomy: Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

Xconomy: Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

Submitted by admin on August 3, 2018 - 11:44am

Source:

Xconomy

News Tags:

hATTR amyloidosis

Headline:

Xconomy: Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

snippet:

By next weekend, the FDA could for the first time approve a medicine that uses a biological trick that was only discovered two decades ago: RNA interference , which silences a gene before it can make a harmful protein. That medicine is patisiran (Onpattro), from Alnylam Pharmaceuticals.